H.C. Wainwright Downgrades Galectin Therapeutics (GALT) to Neutral

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. RNG
2. DECK
3. WDC
4. BMY
5. BYD
6. SPOT
7. WCN
8. TSCO
9. BE
10. SPY

Go back to H.C. Wainwright Downgrades Galectin Therapeutics (GALT) to Neutral

Galectin Therapeutics Announces Top-Line Data from Exploratory Phase 2a Pilot Trial (NASH-FX) with GR-MD-02 in NASH Patients with Advanced Fibrosis

September 27, 2016 4:15 PM EDT

Larger Phase 2b clinical trial in NASH cirrhosis (NASH-CX) now completely enrolled

Closed private placement financing for $1.5 million

Conference call to be held today at 5:30 p.m. (Eastern Time)

NORCOSS, Ga., Sept. 27, 2016 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced topline results from NASH-FX, its Phase 2a clinical trial evaluating the efficacy, safety, and tolerability of GR-MD-02 in 30 nonalcoholic steatohepatitis (NASH) patients with advanced fibrosis.... More